Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.
about
PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilastCOPD exacerbations. 4: PreventionCilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.Bronchiolar chemokine expression is different after single versus repeated cigarette smoke exposureCytokine inhibition in the treatment of COPD.The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophagesDesensitization of beta-adrenergic receptors in lung injury induced by 2-chloroethyl ethyl sulfide, a mustard analog.Inhibition of granulocyte migration by tiotropium bromideABCD of the phosphodiesterase family: interaction and differential activity in COPDAS-703026 Inhibits LPS-Induced TNFα Production through MEK/ERK Dependent and Independent Mechanisms.Differences in local versus systemic TNFalpha production in COPD: inhibitory effect of hyaluronan on LPS induced blood cell TNFalpha release.Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma?Bronchial epithelial spheroids: an alternative culture model to investigate epithelium inflammation-mediated COPD.Chronic obstructive pulmonary disease, inflammation and PDE4 inhibitors.Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast.Aspects on pathophysiological mechanisms in COPD.Autocrine Acetylcholine, Induced by IL-17A via NFκB and ERK1/2 Pathway Activation, Promotes MUC5AC and IL-8 Synthesis in Bronchial Epithelial Cells.Evaluation of PDE4 inhibition for COPD.Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease.Treating COPD with PDE 4 inhibitors.Granulocyte-macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPDTargeted treatment in COPD: a multi-system approach for a multi-system disease.Anti-inflammatory effect of Yu-Ping-Feng-San via TGF-β1 signaling suppression in rat model of COPD.Is 'GOLD' standard for the management of COPD in clinical practice?PDE4: a novel target in the treatment of chronic obstructive pulmonary disease.Pathophysiology of tobacco smoke exposure: recent insights from comparative and redox proteomics.Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation.A novel AMPK activator hernandezine inhibits LPS-induced TNFα production.miR-135b-5p inhibits LPS-induced TNFα production via silencing AMPK phosphatase Ppm1e.Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.Lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers.Oxidative stress is an important component of airway inflammation in mice exposed to cigarette smoke or lipopolysaccharide.Epac Function and cAMP Scaffolds in the Heart and Lung.Effects of Ergosterol on COPD in Mice via JAK3/STAT3/NF-κB Pathway.Fluoxetine, an Antidepressant Drug, Inhibited Cigarette Smoke-Induced Pulmonary Inflammation and Apoptosis in Rats.Chronic obstructive pulmonary disease (COPD): neutrophils, macrophages and lymphocytes in patients with anterior tuberculosis compared to tobacco related COPD.
P2860
Q24646836-CCB2A279-8C80-40FD-B3E5-868FA3C37B10Q30480789-DEC21855-909A-4FF8-9FCB-5A072621B4C9Q33258089-518CF994-9417-406D-B77F-4A7FC36DBBACQ33315589-9047E35D-4959-4562-9F4E-B6E878B20EB3Q33568552-6ED58D6B-5674-4E04-B831-1BEA47263BCEQ33767229-27D9D84B-0772-4E03-9844-8E630BA7ACBDQ33824363-3A482F4E-EB3E-40AB-9729-DDE19940DBCDQ34638204-A7FD43C8-3E44-4593-9349-CDF546671001Q34961511-25C7CDE5-6B10-411E-BA4A-0740280645FBQ35779438-43F9B9CE-DEBD-4B5C-821B-BEF9B0E95D21Q36203159-F5CE6995-EBFB-4A3C-BBEC-60483C70C60DQ36376519-2388832E-97DC-4AA8-80B6-D8287F818A87Q36407068-1268A3D9-511D-4CB9-A8E8-3E33AC0CEAA5Q36554689-E8C881B7-EE49-4784-8B3C-22408967B615Q36677411-21063F02-F163-4FCA-A9BE-ED08861EEC49Q36909567-5AE0201F-10BF-4DC6-BB64-04A5DC00597FQ36958848-65EB2A75-7755-4D87-A6C2-C3960F1C0F8AQ37017332-E810F70B-CDEB-40F8-AAE1-B7BC6D1EE426Q37082562-8E37BEED-A505-4AFB-A28B-728960B4CE08Q37082594-EAFF63E0-E0D3-4E3A-8080-7B4DDE81FB19Q37265525-835F0549-980F-4FB0-AFB4-C2A85218ED0DQ37340178-3EBDBE71-2853-42C7-A9F6-C3F551B99294Q37366460-88D2E2C0-147F-4C18-93D2-30AD82147445Q37450159-52CCF99C-D3E7-442F-85CA-5B28BE2443F1Q37963175-99782D0A-37F9-4B28-B6C0-691868527E21Q38165872-F67ED983-06BF-44DC-A5BF-1146CABE97D1Q38543069-861470E1-457B-43DA-BDD1-F4736B67DD45Q38595360-B68C9730-F29E-4FF1-9BE7-28FEFD230A82Q38755670-4E4CC636-6EF3-44F1-AAD0-A6CDEA81E6F8Q41846937-376516BA-4FB3-4C9A-80B1-E2FE728A38E1Q42314589-997B37B4-8BB4-48D3-B5C6-5B626DD689C1Q43061572-7CE9A0BD-0DB8-428F-9752-95FEB5949FA5Q45022895-1023B0E4-3829-4D2F-B55E-1E897B838069Q46821548-A5F3154A-DABE-4019-99BE-F1E9B0BDA55EQ48104933-CAFD67E2-325E-4656-8847-31EE90A10322Q50983469-824314B8-D119-4018-A2C2-64B1E84070F7Q51017368-DD0659A4-97FB-4D5D-8E1F-73910C1C23ACQ52724030-4B06BB03-5705-42F5-A774-70EE50BFF675
P2860
Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Effect of cilomilast (Ariflo) ...... y cells of patients with COPD.
@ast
Effect of cilomilast (Ariflo) ...... y cells of patients with COPD.
@en
type
label
Effect of cilomilast (Ariflo) ...... y cells of patients with COPD.
@ast
Effect of cilomilast (Ariflo) ...... y cells of patients with COPD.
@en
prefLabel
Effect of cilomilast (Ariflo) ...... y cells of patients with COPD.
@ast
Effect of cilomilast (Ariflo) ...... y cells of patients with COPD.
@en
P2093
P2860
P50
P356
P1433
P1476
Effect of cilomilast (Ariflo) ...... ay cells of patients with COPD
@en
P2093
A M Vignola
F Mirabella
G Costanzo
J Bousquet
L Chimenti
R Di Giorgi
P2860
P304
P356
10.1136/THORAX.58.7.573
P407
P577
2003-07-01T00:00:00Z